KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Retained Earnings (2016 - 2026)

Pacira BioSciences has reported Retained Earnings over the past 17 years, most recently at -$196.4 million for Q1 2026.

  • For Q1 2026, Retained Earnings rose 2.55% year-over-year to -$196.4 million; the TTM value through Mar 2026 reached -$196.4 million, up 2.55%, while the annual FY2025 figure was -$199.3 million, 3.41% up from the prior year.
  • Retained Earnings for Q1 2026 was -$196.4 million at Pacira BioSciences, up from -$199.3 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $4.1 million in Q3 2025 and troughed at -$206.4 million in Q2 2025.
  • A 5-year average of -$96.5 million and a median of -$106.8 million in 2023 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: soared 6880.0% in 2024 and later plummeted 196662.86% in 2025.
  • Year by year, Retained Earnings stood at -$148.8 million in 2022, then grew by 28.2% to -$106.8 million in 2023, then plummeted by 93.22% to -$206.4 million in 2024, then rose by 3.41% to -$199.3 million in 2025, then increased by 1.46% to -$196.4 million in 2026.
  • Business Quant data shows Retained Earnings for PCRX at -$196.4 million in Q1 2026, -$199.3 million in Q4 2025, and $4.1 million in Q3 2025.